Opcjonalna analityka produktu
Za zgodą użytkownika stosujemy ograniczoną analitykę chroniącą prywatność, aby zrozumieć, które ścieżki badawcze działają. Nie używamy trackerów reklamowych ani nagrywania sesji. Ten wybór można zmienić w Preferencjach. Przeczytaj Politykę prywatności.
Alexandria Real Estate Equities Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $7.2B | |
|---|---|---|
| Revenue (ttm) | 2.8B | |
| Net income (ttm) | -1.4B | |
| EPS (ttm) | -$8.40 | |
| Shares out | 174.2M | |
| P/E (forward) | 16.7x | |
| Dividend | $2.88 (7.26%) | |
| Volume | 5,026,386 | |
| Beta | 1.18 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.11B | $2.58B | $2.84B | $3.05B | $2.97B | +8.9% |
| Gross profit | $1.49B | $1.79B | $1.98B | $2.14B | $2.05B | +8.3% |
| Operating income | $530.3M | $764.9M | $355.2M | $696.6M | $-990.0M | — |
| Net income | $571.2M | $521.7M | $103.6M | $322.9M | $-1.43B | — |
| EPS (diluted) | $3.82 | $3.18 | $0.54 | $1.80 | $-8.44 | — |
| EBITDA | $1.35B | $1.77B | $1.45B | $1.90B | $360.5M | -28.1% |
| R&D | $0 | $0 | $0 | — | — | -73.6% |
| SG&A | $151.5M | $177.3M | $199.4M | $168.4M | $117.0M | -6.2% |
Recent company headlines from major financial publishers.
In the Base case, Alexandria achieves Fair value of $43.02 representing a return of 3.4% with a probability of 55.0%. This path requires steady lease absorption across the development pipeline, normalization of construction capital expenditures toward guided levels, and successful completion of planned capital recycling to stabilize leverage. The scenario would be disconfirmed if cash renewal spreads deteriorate deeper than expected or if tenant downtime extends across upcoming expirations.
In the Bull case, Alexandria reaches Potential value of $49.06 representing an attractive return of 17.9% with a probability of 20.0%. This outcome requires a strong rebound in biotechnology venture funding that accelerates life science leasing, returns cash renewal spreads to positive territory, and allows expedited debt repayment through premium asset valuations. The path would be disconfirmed if secondary submarket lab vacancy persists and renewal spreads remain constrained.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.2% | $47.3 | $48.8 | $50.5 | $52.4 | $54.4 |
| 8.7% | $43.8 | $45.1 | $46.5 | $48.0 | $49.7 |
| 9.2% | $40.7 | $41.8 | $43.0 | $44.3 | $45.7 |
| 9.7% | $38.1 | $39.0 | $40.1 | $41.1 | $42.3 |
| 10.2% | $35.8 | $36.6 | $37.5 | $38.4 | $39.4 |
Upcoming earnings date and setup when available.
Rekomendacja, którą nosiło opublikowane w danym miesiącu wydanie analizy. Rekomendacja porównuje cenę z dnia analizy z wartością godziwą; nie jest zapisem tego, czy ocena się sprawdziła.
| Rok | sty | lut | mar | kwi | maj | cze | lip | sie | wrz | paź | lis | gru |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
